However, other biologics are indicated for specific phenotypes of type 2 severe asthma: omalizumab (Xolair®), which is an anti-Ig-E antibody for the treatment of allergic asthma, and benralizumab (Fasenra®), reslizumab (Cinqair®), and mepolizumab (Nucala®), which are anti-IL-5 antibodies for treating eosinophilic asthma [8, 9]. This evidence concerns the gene IL5 and asthma.